Sesotho
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Lihlahisoa tsa lihlopha
Lihlahisoa tse hlahisitsoeng
Matlapa a Lenopril a Matlafatsang Taolo ea Khatello ea Mali le Bophelo bo Botle ba Pelo

Matlapa a Lenopril a Matlafatsang Taolo ea Khatello ea Mali le Bophelo bo Botle ba Pelo
Telmisartan Betere antihypertensive Ho sireletsa renal

Telmisartan Betere antihypertensive Ho sireletsa renal
Flumazenil Mohanyetsi oa Moamoheli oa GABAA ea Khethiloeng le Likopo tsa eona tsa Phekolo

Flumazenil Mohanyetsi oa Moamoheli oa GABAA ea Khethiloeng le Likopo tsa eona tsa Phekolo
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated

Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated
Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic

Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic
Cisapride Gastric Stimulant bakeng sa Indigestion le Mathata a Ts'ila

Cisapride Gastric Stimulant bakeng sa Indigestion le Mathata a Ts'ila
YK-11 SARM e Matla bakeng sa Kaho ea mesifa, Matla a Matla, le Myostatin Inhibition

YK-11 SARM e Matla bakeng sa Kaho ea mesifa, Matla a Matla, le Myostatin Inhibition
Ostarine (MK-2866) SARM e fapaneng bakeng sa Khōlo ea Mesifa, Tahlehelo ea Mafura le 'Mele oa Recomposition

Ostarine (MK-2866) SARM e fapaneng bakeng sa Khōlo ea Mesifa, Tahlehelo ea Mafura le 'Mele oa Recomposition
MK-677 Motsoako o Ikhethileng oa Khōlo ea Mesifa, Mamello, le Pholiso

MK-677 Motsoako o Ikhethileng oa Khōlo ea Mesifa, Mamello, le Pholiso
0102030405
Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated
Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated
Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated
Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated

Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated

Theko e Ikhethileng: USD 50-60 / kg

  • Lebitso la Sehlahiswa Dabrafenib
  • Nomoro ea CAS. 1195765-45-7
  • MF Setšoantšo sa C23H20F3N5O2S2
  • MW 519.561
  • EINECS 1592732-453-0
  • Botenya 1.443
  • Ntho e belang 653.726 °C ho 760 mmHg
Iteanye le rona
lintlha tsa sehlahisoa

Tlhaloso e Felletseng

Dabrafenib ke inhibitor ea molomo ea bioavailable ea protheine ea B-raf (BRAF) 'me e sebelisoa e le moriana o thibelang mofetše. E khetha ka ho khetheha liphatsa tsa lefutso tse amanang le mofuta o fetotsoeng oa mofuta oa BRAF. Sengoliloeng sena se hlahloba mokhoa oa ts'ebetso, matšoao a bongaka, le ts'ebeliso ea dabrafenib kalafong ea mefuta e fapaneng ea mofetše.

I. Ho utloisisa Dabrafenib:
A. Inhibitor ea protheine ea B-raf (BRAF).
B. Mokhoa oa ts'ebetso: Ho thibela pontšo e sa tloaelehang ea protheine le ho laola kholo ea lisele

17159473034104h3

II. Matšoao a Kliniki:

A. Monotherapy:

Melanoma e sa senyeheng kapa ea metastatic e nang le phetoho ea BRAF V600E

B. Phekolo e kopaneng le trametinib:

BRAF V600E-positive unrectable kapa metastatic melanoma

Kankere ea matšoafo ea metastatic e seng e nyane

Metastatic anaplastic kankere ea qoqotho

Lihlahala tse tiileng tse ke keng tsa qojoa kapa tsa metastatic


III. Mokhoa oa ts'ebetso:

A. Khetho e tlamang le ho thibela B-raf

B. Thibelo ea ho ata ha lisele tsa tumor ka liphatsa tsa lefutso tsa BRAF tse fetotsoeng


IV. Kalafo ea Kankere ea Thyroid:

A. Mofuta o itseng oa kankere ea qoqotho e nametse liseleng tse haufi kapa likarolong tse ling tsa 'mele

B. Kalafo e fetileng (s) khanyetso


Sehlopha sa V. Kinase Inhibitor:

A. Dabrafenib e le setho sa kinase inhibitors

B. Ho thibela ketso e sa tloaelehang ea protheine ho thibela ho ata ha lisele tsa mofetše


Dabrafenib ke kalafo e lebisitsoeng ho sebelisoa kalafo ea mofets'e o fetotsoeng oa BRAF. Joaloka inhibitor ea protheine ea B-raf (BRAF), e khetha ka ho khetheha lisele tsa tumor tse nang le gene ea BRAF e fetotsoeng, e thibelang ho ata ha tsona. Dabrafenib e bontšoa bakeng sa melanoma e ke keng ea qojoa kapa ea metastatic, kankere e seng e nyenyane ea lisele tsa matšoafo, kankere ea qoqotho ea anaplastic, le lihlahala tse tiileng tse sa tsitsang kapa tse metastatic. Phekolo e kopaneng le trametinib e eketsa ts'ebeliso ea eona. Ka ho utloisisa liphetoho tse khethehileng tsa lefutso liseleng tsa mofetše, liphekolo tse lebisitsoeng joalo ka dabrafenib li bapala karolo ea bohlokoa ho ntlafatseng sephetho sa kalafo le ho thibela ho ata ha lisele tsa mofetše.

Tlhaloso

1715947563669qd1